PAC1R antagonist 1

CAS No. 2305204-24-2

PAC1R antagonist 1( —— )

Catalog No. M37140 CAS No. 2305204-24-2

PAC1R antagonist 1 is an orally active PAC1 receptor antagonist that inhibits abnormal pain induced by pituitary adenylate cyclase-activating polypeptide (PACAP) and nerve damage, and may be used in the study of neoplasms and immune-related disorders.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 226 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    PAC1R antagonist 1
  • Note
    Research use only, not for human use.
  • Brief Description
    PAC1R antagonist 1 is an orally active PAC1 receptor antagonist that inhibits abnormal pain induced by pituitary adenylate cyclase-activating polypeptide (PACAP) and nerve damage, and may be used in the study of neoplasms and immune-related disorders.
  • Description
    PAC1R antagonist 1 (compound 3d) is a potent and orally active antagonist of PAC1 receptor. PAC1R antagonist 1 can inhibit pituitary adenylate cyclase-activating polypeptide (PACAP)- and nerve injury-induced allodynia.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    PACAP
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2305204-24-2
  • Formula Weight
    372.81
  • Molecular Formula
    C17H17ClN6O2
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 33.33 mg/mL (89.40 mM; ultrasonic and warming and heat to 160°C )
  • SMILES
    O=C(NCCC1=CN=CN1)C2CC(=O)N(C3=NNC=4C(Cl)=CC=CC34)C2
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Takasaki I, et, al. Synthesis of a novel and potent small-molecule antagonist of PAC1 receptor for the treatment of neuropathic pain. Eur J Med Chem. 2020 Jan 15;186:111902. ?
molnova catalog
related products
  • Thalidomide-O-amido-...

    Thalidomide-O-amido-C6-NH2 TFA, a synthesized E3 ligase ligand-linker conjugate containing a Thalidomide-based cereblon ligand and a linker.

  • Semustine

    Semustine, a DNA alkylating agent, is a cancer chemotherapy compound that is nephrotoxic in patients with malignant melanoma receiving adjuvant chemotherapy for the adjuvant treatment of leukemia.

  • Lucerastat

    A galactose analogue that is an UDP-glucose ceramide glucosyltransferase (UGCG/GCS) inhibitor (IC50=41.4 uM).